1887

Abstract

Invasive meningococcal disease (IMD) caused by may show temporal and geographical changes in both the epidemiology and the characteristics of the strains involved.

A study that examined invasive causing IMD in Atlantic Canada from 2009 to 2013 was published in 2014. Data from subsequent years have not been described.

This study examined the molecular epidemiology of IMD in four Atlantic Provinces of Canada as well as potential serogroup B (MenB) vaccine coverage.

Individual IMD case isolates recovered from 2014 to 2020 were analysed for serotype and serosubtype antigens as well as by whole-genome sequencing (WGS) for prediction of potential MenB vaccine coverage.

Of the 56 IMD isolates, 42, 8, 5 and 1 were MenB, serogroup Y, serogroup W (MenW) and serogroup C, respectively. Geographical differences in the distribution of MenB clones revealed concentration of sequence type (ST)-269 clonal complex (cc) and ST-60 cc in Newfoundland and Labrador, while ST-41/44 cc (particularly ST-154) was predominantly found in New Brunswick and Nova Scotia. Core genome multi-locus sequence typing (cgMLST) also separated the New Brunswick and Nova Scotia ST-154 isolates into two clusters, with differences in their and alleles. Furthermore, cgMLST also separated the ST-269 cc isolates in Atlantic Canada into the ST-1611 and the ST-269/ST-8924 clusters, with the latter showing high similarity to the ST-269 that first emerged in the Province of Quebec. Genetic Meningococcal Antigen Typing System showed that 54.8 % of MenB were predicted to be covered by the MenB vaccine Bexsero, with a further 38.1 % potentially covered by virtue of the presence of genes that encoded factor H-binding protein variant 1 proteins. Meningococcal deduced vaccine antigen reactivity predicted from WGS data showed that 95.3 % of MenB were covered by Trumenba. Four cases of IMD due to MenW ST-11 cc were also identified, with the first case found in 2018.

This study provided evidence concerning the dynamics of strains causing IMD in Atlantic Canada, with both geographical and temporal differences found. MenB vaccine appeared to provide good coverage of MenB IMD, especially towards the predominant strain of ST-154.

  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001615
2022-12-16
2024-12-05
Loading full text...

Full text loading...

/deliver/fulltext/jmm/71/12/jmm001615.html?itemId=/content/journal/jmm/10.1099/jmm.0.001615&mimeType=html&fmt=ahah

References

  1. Tsang RSW, Law DKS, De Paola R, Giuliani M, Stella M et al. Culture-confirmed invasive meningococcal disease in Canada, 2010 to 2014: characterization of serogroup B Neisseria meningitidis strains and their predicted coverage by the 4CMenB vaccine. mSphere 2020; 5:e00883-19 [View Article]
    [Google Scholar]
  2. De Wals P. Epidemiology and control of meningococcal disease in Canada: a long, complex, and unfinished story. Can J Infect Dis Med Microbiol 2019; 2019:8901847 [View Article]
    [Google Scholar]
  3. Giuliani MM, Adu-Bobie J, Comanducci M, Aricò B, Savino S et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci 2006; 103:10834–10839 [View Article]
    [Google Scholar]
  4. Pillai S, Howell A, Alexander K, Bentley BE, Jiang H-Q et al. Outer membrane protein (OMP) based vaccine for Neisseria meningitidis serogroup B. Vaccine 2005; 23:2206–2209 [View Article] [PubMed]
    [Google Scholar]
  5. Public Health Agency of Canada The recommended use of the multicomponent meningococcal B (4CMenB) vaccine in Canada: common guidance statement; 2014Mar26 https://publications.gc.ca/collections/collection_2014/aspc-phac/HP40-103-2014-eng.pdf
  6. Harrison R, Stirling R, Baclic O, Vaudry W. Summary of the NACI statement on the use of bivalent factor H binding protein meningococcal serogroup B (MenB-fHBP) vaccine for the prevention of meningococcal B disease. Can Commun Dis Rep 2020; 46:36–39 [View Article]
    [Google Scholar]
  7. Tsang RSW, Law DKS, Gad RR, Mailman T, German G et al. Characterization of invasive Neisseria meningitidis from Atlantic Canada, 2009 to 2013: With special reference to the nonpolysaccharide vaccine targets (PorA, factor H binding protein, Neisseria heparin-binding antigen and Neisseria adhesin A). Can J Infect Dis Med Microbiol 2015; 26:299–304 [View Article] [PubMed]
    [Google Scholar]
  8. Zhou J, Lefebvre B, Deng S, Gilca R, Deceuninck G et al. Invasive serogroup B Neisseria meningitidis in Quebec, Canada, 2003 to 2010: persistence of the ST-269 clone since it first emerged in 2003. J Clin Microbiol 2012; 50:1545–1551 [View Article] [PubMed]
    [Google Scholar]
  9. Law DKS, Lorange M, Ringuette L, Dion R, Giguère M et al. Invasive meningococcal disease in Quebec, Canada, due to an emerging clone of ST-269 serogroup B meningococci with serotype antigen 17 and serosubtype antigen P1.19 (B:17:P1.19). J Clin Microbiol 2006; 44:2743–2749 [View Article] [PubMed]
    [Google Scholar]
  10. Maiden MCJ, Bygraves JA, Feil E, Morelli G, Russell JE et al. Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms. Proc Natl Acad Sci 1998; 95:3140–3145 [View Article]
    [Google Scholar]
  11. Lucidarme J, Hill DMC, Bratcher HB, Gray SJ, du Plessis M et al. Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage. J Infect 2015; 71:544–552 [View Article]
    [Google Scholar]
  12. Vogel U, Claus H, Frosch M, Caugant DA. Molecular basis for distinction of the ET-15 clone within the ET-37 complex of Neisseria meningitidis. J Clin Microbiol 2000; 38:941–942 [View Article]
    [Google Scholar]
  13. Gilca R, Deceuninck G, Lefebvre B, Tsang R, Amini R et al. The changing epidemiology of meningococcal disease in Quebec, Canada, 1991-2011: potential implications of emergence of new strains. PLoS One 2012; 7:1–9 [View Article] [PubMed]
    [Google Scholar]
  14. Matthews TC, Bristow FR, Griffiths EJ, Petkau A, Adam J et al. The integrated rapid infectious disease analysis (IRIDA) platform. Bioinformatics 2018 [View Article]
    [Google Scholar]
  15. Jolley KA, Maiden MCJ. BIGSdb: Scalable analysis of bacterial genome variation at the population level. BMC Bioinformatics 2010; 11:595 [View Article]
    [Google Scholar]
  16. Brehony C, Rodrigues CMC, Borrow R, Smith A, Cunney R et al. Distribution of Bexsero® antigen sequence types (BASTs) in invasive meningococcal disease isolates: implications for immunisation. Vaccine 2016; 34:4690–4697 [View Article]
    [Google Scholar]
  17. Muzzi A, Brozzi A, Serino L, Bodini M, Abad R et al. Genetic meningococcal antigen typing system (gMATS): a genotyping tool that predicts 4CMenB strain coverage worldwide. Vaccine 2019; 37:991–1000 [View Article]
    [Google Scholar]
  18. Rodrigues CMC, Jolley KA, Smith A, Cameron JC, Feavers IM et al. Meningococcal deduced vaccine antigen reactivity (MenDeVAR) index: a rapid and accessible tool that exploits genomic data in public health and clinical microbiology applications. J Clin Microbiol 2020; 59:e02161–e02173 [View Article]
    [Google Scholar]
  19. Tsang R, Hoang L, Tyrrell GJ, Horsman G, Van Caeseele P et al. Increase in Neisseria meningitidis serogroup W invasive disease in Canada: 2009-2016. Can Commun Dis Rep 2017; 43:144–149 [View Article]
    [Google Scholar]
  20. Booy R, Gentile A, Nissen M, Whelan J, Abitbol V. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum Vaccin Immunother 2019; 15:470–480 [View Article] [PubMed]
    [Google Scholar]
  21. Taha M-K, Deghmane A-E, Knol M, van der Ende A. Whole genome sequencing reveals Trans-European spread of an epidemic Neisseria meningitidis serogroup W clone. Clin Microbiol Infect 2019; 25:765–767 [View Article] [PubMed]
    [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001615
Loading
/content/journal/jmm/10.1099/jmm.0.001615
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error